Sandoz stock: Brazil semaglutide launch opens new GLP-1 route

Sandoz launched Owozy, its semaglutide solution for injection, in Brazil on Monday, November 9, 2026. The company announced the launch in a release under the SIX Swiss Exchange Listing Rules, saying the product expands access to a new treatment option in a major GLP-1 market. Sandoz developed the launch with Adalvo and local commercial partner Biolab & Co.

New GLP-1 Market Entry

Owozy received approval from Brazil's Agência Nacional de Vigilância Sanitária on July 29, 2026, for adults with type-2 diabetes. The medicine is supplied in pre-filled, multi-dose disposable pens and is administered once weekly alongside diet and exercise, in line with approved product information and medical advice.

Sandoz estimates the Brazilian GLP-1 market at 2.7 billion US dollars. The company said more than 16.5 million adults in Brazil live with diabetes, while more than five million are estimated to remain undiagnosed. Access, competition and reimbursement conditions will determine the commercial pace.

Limited Near-Term Earnings Effect

Sandoz expects no material financial contribution from the semaglutide launch this year. For investors, the announcement therefore adds a longer-term growth option rather than an immediate earnings driver. Prescription uptake, distribution performance and the planned expansion of the GLP-1 portfolio are the next milestones.

Sandoz stock traded at 91.83 euros on Lang & Schwarz at 17:31 CET on Monday, November 9, 2026, 1.30 percent below the Xetra close of 93.04 euros on Friday, November 6. The quote was 1.23 percent below the 92.97-euro Lang & Schwarz price cited at 11:01 CET in the previous report on the Brazil launch.

Swiss equities can be followed through the SMI market overview.

More news and analyses on Sandoz stock